New Treatment for Inflammation in Middle Ear Infections

中耳感染炎症的新治疗方法

• 批准号: 7008203
• 负责人: SHARON L MCCOY
• 金额: $ 31.24万
• 依托单位: 13THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-01-15 至 2007-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7008203
• 关键词: antiinfective agents; antiinflammatory agents; bacteria infection mechanism; drug design /synthesis /production; drug screening /evaluation; ear infection; fluid; gram negative bacteria; gram positive bacteria; host organism interaction; inflammation; laboratory mouse; microorganism disease chemotherapy; nonhuman therapy evaluation; otitis media; antiinfective agents; antiinflammatory agents; bacteria infection mechanism; drug design /synthesis /production; drug screening /evaluation; ear infection; fluid; gram negative bacteria; gram positive bacteria; host organism interaction; inflammation; laboratory mouse; microorganism disease chemotherapy; nonhuman therapy evaluation; otitis media

DESCRIPTION (provided by applicant): Bacterial infections are the primary cause of otitis media with effusion (OME), an inflammatory disease of the middle ear. OME is characterized by production of pro-inflammatory cytokines within the middle ear and development of inflammation and fluid accumulation. While the primary treatment for OME is antibiotics, there is no therapy that directly targets the inflammation and fluid accumulation. This Phase II proposal will provide pre-clinical assessment of a therapy to treat bacterial-induced inflammation. Targeted Gene Delivery has developed a novel peptide drug that specifically blocks the intracellular signaling and cell activation (production of pro-inflammatory cytokines) that results from the interaction of bacteria and immune cells. Preliminary in vivo studies demonstrated a significant anti-inflammatory effect in a mouse model of bacterial induced OME, with marked reduction in fluid accumulation, number of inflammatory cells, and mucosal thickening in the middle ear. In the current study, experiments will test the efficacy of this therapy in reducing inflammation in a mouse model of bacterial-induced OME and the impact of this novel therapy on improving hearing thresholds. These studies have the potential to define a new approach to treating bacterial-induced inflammation that will have application in OME and a variety of other inflammatory diseases.

描述（由申请人提供）：细菌感染是中耳炎性疾病的中耳炎（OME）中耳炎的主要原因。 OME的特征是中耳内促炎性细胞因子的产生以及炎症和液体积累的发展。虽然对OME的主要治疗方法是抗生素，但尚无直接靶向炎症和液体积累的疗法。该II期建议将对治疗细菌诱发的炎症的治疗进行临床前评估。靶向基因递送已经开发了一种新型的肽药物，该药物专门阻断了细胞内信号传导和细胞激活（促炎性细胞因子的产生），该药物是由细菌和免疫细胞相互作用引起的。初步体内研究表明，在细菌诱导的小鼠模型中具有显着的抗炎作用，其中液体积累，炎性细胞的数量和中耳中粘膜增厚明显减少。在当前的研究中，实验将测试这种疗法在减少细菌诱导的OME小鼠模型中炎症的功效，以及这种新型疗法对改善听力阈值的影响。这些研究有可能定义一种治疗细菌诱导的炎症的新方法，该方法将在OME和多种其他炎症性疾病中应用。